CAMP4 Therapeutics (CAMP) vs MacroGenics (MGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MacroGenics (MGNX) has outperformed CAMP4 Therapeutics (CAMP) over the past year, gaining 99.4% versus a gain of 4.5%. CAMP4 Therapeutics is the larger company by market cap ($232.2 million vs $226.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | MGNX |
|---|---|---|
| Share price | $3.70 | $3.55 |
| Market cap | $232.19M | $226.14M |
| 1-day change | -3.65% | 0.00% |
| YTD return | -39.64% | +120.50% |
| 1-year return | +4.52% | +99.44% |
| 5-year return | — | -82.02% |
| EPS (TTM) | $-2.32 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $5.08 |
| 52-week low | $2.86 | $1.29 |
| Distance from 52-week high | -52.26% | -30.12% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +185.68% | +125.35% |
| Average volume | 277.90K | 621.73K |
| Shares outstanding | 62.75M | 63.70M |
| Employees | 48 | 293 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGNX has outperformed CAMP by 94.9 percentage points over the past year.
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
CAMP vs MGNX FAQ
Which is bigger, CAMP4 Therapeutics or MacroGenics?
CAMP4 Therapeutics (CAMP) is larger, with a market capitalization of $232.19M compared with $226.14M for MacroGenics (MGNX).
Which stock has performed better over the past year, CAMP or MGNX?
MGNX returned +99.44% over the past 12 months, compared with +4.52% for CAMP (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and MacroGenics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.